UK
Lee Ann Steadman
I co-lead the expansion of LCP’s pricing, reimbursement, and market access services in the United States.
With more than twenty years of industry experience, I am a seasoned professional with expertise in US Market Access, encompassing payer, trade, and channel strategies, as well as patient services. I have successfully launched more than 50 products, demonstrating my profound knowledge and strategic acumen across various therapeutic areas, including oncology, neurology, immunology, dermatology, and rare diseases.
Throughout my career, I have been instrumental in shaping market access strategies that ensure patients have timely and affordable access to innovative treatments. My deep understanding of the healthcare landscape and ability to navigate complex regulatory environments have made me a trusted leader in the field.
My commitment to improving patient outcomes is evident in my work, where I consistently strive to bridge the gap between pharmaceutical innovation and patient needs. My collaborative approach and dedication to excellence have earned recognition and respect among peers and stakeholders alike.
Before joining LCP, I served as Sr. Vice President of Specialty Consulting at EVERSANA, where I led US market access with an emphasis on patient services, Trade and Channel efforts. I joined EVERSANA in 2021 when Protean was acquired by them. At Protean I last served as an equity partner helping build the company to successfully deliver client satisfaction across their suite of services.
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Is trade strategy part of your C-suite dialogue, and is it at a market or global level?
Natalie Rush explains why trade strategy must be a C-suite priority for pharma leaders, showing how aligning commercial, market access, and operational pathways can accelerate speed to market, control costs, and expand patient access globally.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
